Search

Your search keyword '"Kungen Wang"' showing total 2 results
Start Over Author "Kungen Wang" Topic fatty liver
2 results on '"Kungen Wang"'

1. Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS/TLR4 signaling pathway

Author

Kungen Wang, Yihui Zhi, Huang Liquan, Shen Wei, and Shen Shuhua

Subjects
Lipopolysaccharides, Male, 0301 basic medicine, medicine.medical_specialty, Cell Survival, Biology, Diet, High-Fat, Transfection, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Internal medicine, Lipid droplet, Nonalcoholic fatty liver disease, medicine, Animals, Humans, Oil Red O, Rats, Wistar, Molecular Biology, Cell Line, Transformed, Triglyceride, Plant Extracts, Fatty liver, Lipid metabolism, Cell Biology, medicine.disease, Gynostemma, Rats, Toll-Like Receptor 4, Disease Models, Animal, Treatment Outcome, 030104 developmental biology, Endocrinology, chemistry, 030220 oncology & carcinogenesis, Hepatocytes, TLR4, lipids (amino acids, peptides, and proteins), Liver function, Research Paper, Drugs, Chinese Herbal, Phytotherapy, Signal Transduction, Developmental Biology
Abstract

Background The contents of lipopolysaccharide (LPS) and Toll-like receptor 4 (TLR4) are significantly increased during the progression of nonalcoholic fatty liver disease (NAFLD). The study investigated the role of the LPS/TLR4 signaling pathway in improving gypenosides (Gyp) on NAFLD. Methods NAFLD model were established in rats and treated by Gyp. Pathological changes of liver tissues were observed by Hematoxylin and Eosin (HE) staining. Lipid metabolism and insulin resistance were measured. Expressions of inflammatory factors and protein of LPS/TLR4 downstream pathway were detected by qRT-PCR and Western blotting. THLE-2 cells were treated by free-fatty acid (FFA), Gyp, and LPS, and then transfected with TLR4. Next, cell viability was detected by MTT. Lipid droplet deposition and Triglyceride (TG) content were determined by Oil Red O staining and ELISA. Results Gyp protected fatty liver tissues in NAFLD model, and significantly reversed cholesterol increased by high-fat diet. Moreover, Gyp increased SOD content and decreased the contents of AST, ALT, MDA, HSI, FBG, FINS, HOMA-IR, IL-1β, and TNF-α, and promoted the expressions of TLR4, LPS, MyD88, p-IκBα, and reduced the expressions of p-p65 and IκBα in the NAFLD model. Gyp treatment significantly reduced lipid droplet deposition, increased TG content and MyD88, p-IκBα, p-p65 in FFA-induced liver cells, but LPS and TLR4 greatly reversed improvement of FFA by Gyp. Conclusion Gypenosides could improve liver function, lipid metabolism, insulin resistance, and levels of inflammatory factors in NAFLD model by regulating LPS/TLR4 signaling pathway in vitro and in vivo.

Published
2020

2. Gypenosides counteract hepatic steatosis and intestinal barrier injury in rats with metabolic associated fatty liver disease by modulating the adenosine monophosphate activated protein kinase and Toll-like receptor 4/nuclear factor kappa B pathways.

Author

Shuhua Shen, Kungen Wang, Yihui Zhi, and Yue Dong

Subjects
*NF-kappa B, *FATTY liver, *OCCLUDINS, *ADENOSINE monophosphate, *NON-alcoholic fatty liver disease, *PROTEIN kinases, *TOLL-like receptors
Abstract

Context: Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease, can develop into metabolic associated fatty liver disease (MAFLD). Gypenosides (GP), the main phytochemical component of Gynostemma pentaphylla (Thunb.) Makino (Cucurbitaceae), have been applied for treatment of metabolic diseases. Objective: We investigate how GP modulate MAFLD-related hepatic steatosis and intestinal barrier injury. Materials and methods: In cell experiments, Caco-2 cells were treated with GP (150 or 200 lmol/L, 24 h), following lipopolysaccharide (LPS) exposure (10 lg/mL, 24 h) to mimic MAFLD in vitro. In in vivo experiments, control, model and modelþGP groups were set. High fructose diet/high fat (HFD/HF)-fed (12 weeks) MAFLD rats received GP treatment (300mg/kg, 6 weeks), followed by intra-peritoneal glucose tolerance test and histopathological examination of rat liver and intestinal mucosa using haematoxylin-eosin staining. Results: GP at 200 lM significantly reversed LPS-induced decreases in transepithelial electrical resistance (TER) value (25%), protein expression of occludin (two fold) and ZO-1 (four fold), and the ratio of p-AMPK to AMPK (five fold), while partially repressing LPS-induced leakage of FD4 (50%) and LPS-induced increases in the Toll-like receptor 4 (TLR4) level (50%) and the ratio of p-p65 to p65 (55%). Compared with the model rats, rats with GP treatment presented a reduction in gain of weight and glucose tolerance. In addition, GP alleviated HFD/HF-induced histopathological abnormalities in rat liver and intestinal mucosa. Conclusions: GP attenuates hepatic steatosis and intestinal barrier injury in MAFLD rats via the AMPK and TLR4/nuclear factor kappa B (NF-jB) pathways, providing a potential treatment for MAFLD patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results